CN104688978B - A kind of Chinese medicine composition for the treatment of congestive heart failure and preparation method thereof - Google Patents
A kind of Chinese medicine composition for the treatment of congestive heart failure and preparation method thereof Download PDFInfo
- Publication number
- CN104688978B CN104688978B CN201510149372.5A CN201510149372A CN104688978B CN 104688978 B CN104688978 B CN 104688978B CN 201510149372 A CN201510149372 A CN 201510149372A CN 104688978 B CN104688978 B CN 104688978B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- heart failure
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 39
- 206010007559 Cardiac failure congestive Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 241001412627 Adenophora liliifolia Species 0.000 claims abstract description 8
- 240000005528 Arctium lappa Species 0.000 claims abstract description 8
- 235000003130 Arctium lappa Nutrition 0.000 claims abstract description 8
- 241000209120 Cenchrus Species 0.000 claims abstract description 8
- 235000006287 Hookers bur ragweed Nutrition 0.000 claims abstract description 8
- 241000521581 Millettia Species 0.000 claims abstract description 8
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 8
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 8
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 8
- 241001522129 Pinellia Species 0.000 claims abstract description 8
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 8
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 8
- 241000405414 Rehmannia Species 0.000 claims abstract description 8
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 7
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 7
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 7
- 244000197580 Poria cocos Species 0.000 claims abstract description 7
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 7
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 6
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 6
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 5
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 5
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 5
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 5
- 241000545442 Radix Species 0.000 claims abstract description 3
- 235000002020 sage Nutrition 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 240000007164 Salvia officinalis Species 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 235000005412 red sage Nutrition 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 241001251949 Xanthium sibiricum Species 0.000 claims 1
- 229940126678 chinese medicines Drugs 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 9
- 230000002861 ventricular Effects 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 7
- 238000003304 gavage Methods 0.000 description 6
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical group COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 229960004195 carvedilol Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 206010037833 rales Diseases 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 206010001029 Acute pulmonary oedema Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 206010013012 Dilatation ventricular Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010013971 Dyspnoea exertional Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010031123 Orthopnoea Diseases 0.000 description 1
- 208000004327 Paroxysmal Dyspnea Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 208000012144 orthopnea Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of Chinese medicines, be specifically related to a kind of Chinese medicine composition for the treatment of congestive heart failure and preparation method thereof and application. Of the present inventionly provide a kind of Chinese medicine composition for the treatment of congestive heart failure, it comprises 15 parts, following component Poria cocos, 8 parts, lotus leaf, 11 parts of sandburs, 12 parts of the Radixs Astragali, 9 parts of the roots of kudzu vine, 20 parts of the reds sage root, 15 parts, the dried rhizome of rehmannia, 13 parts of peppermints, 5 parts of great burdock achenes, 5 parts of ginkgo leaves, 10 parts of the root of straight ladybell, 12 parts, date, 8 parts of pinellias, 9 parts of reticulate millettias, 5 parts of Radix Angelicae Sinensis, 4 parts of pseudo-ginseng, 10 parts, Radix Glycyrrhizae. This Chinese medicine composition, having good result for the treatment of aspect treatment congestive heart failure, has significant clinical generalization value.
Description
Technical field
The invention belongs to field of medicaments, relate to a kind of Chinese medicine composition and preparation method thereof, be specifically related to one and treat congestedChinese medicine composition in heart failure and preparation method thereof and application.
Background technology
Heart failure claims again " myocardial failure ", refers to that heart can not put out same venous return and the required phase of bodily tissue metabolism at that timeThe blood supply claiming. Often cause that by various diseases cardiac contractility ability weakens, thereby the blood output quantity of heart reduced,Be not enough to meet the needs of body, and produce thus series of symptoms and sign. Heart valve disease, coronary sclerosis, heightBlood pressure, endocrine illness, bacteriotoxin, acute lung infraction, pulmonary emphysema or other chronic lungs illness etc. all can cause heartSick and produce performance in heart failure. Gestation, fatigue, the rapidly a large amount of fluid infusion of intravenous etc. all can increase the weight of the burden of ill heart,And bring out heart failure.
The clinical manifestation of congestive heart failure is: 1. expiratory dyspnea and weak: most heart failure patients decline because of exercise toleranceAnd there is expiratory dyspnea or weak symptom and seeking medical advice. Under rest situation, severe patient also has symptom, can also occur suppressing night awake.2. edema of lower extremity: fluid retention symptom may appear in patient, as shank or abdominal swelling etc., and as primary or only symptomSeek medical advice. These patients' exercise tolerance reduction occurs gradually. 3. the disease due to asymptomatic or other heart diseases or non-heart diseaseShape: in the time checking the other diseases such as acute myocardial infarction AMI, arrhythmia cordis or lung or body thrombotic disease, just findThese patients have heart to expand or insufficiency performance. 4. the Early manifestation that heart failure increases the weight of: the early stage sign that left heart function reduces is:In the time that original heart function is normal, occur that the reduction of tired or exercise tolerance and the heart rate of unknown cause increases by 15～20 beats/min. ContinueSleeping and need raising head, exertional dyspnea, nocturnal paroxysmal dyspnea etc. with pillow appears in supervention exhibition; Having a medical check-up canSee left ventricular enlargement, news and diastole cantering rhythm in early stage or mid-term, two lungs especially base of lung portion have moist rales, also can have dry rale andWheezing sound, prompting left heart function obstacle. 5. acute pulmonary edema: onset is anxious, and PD is rapid. Burst severe dyspnea,Orthopnea, dysphoria are with fear, and respiratory rate can reach 30～50 beats/min; Frequently cough and bring up a large amount of pinkFrothy sputum; Auscultation heart rate is fast, apex Chang Kewen and cantering rhythm; Two lungs are abound with moist rales and wheezing sound.
Clinically treatment in heart failure is mainly increased to cardiac contractile force by the reasonable vasodilator that uses at present, improve the heartFunction. Conventional therapy in heart failure is to make diuretics, ACEI (or ARB) and three combining of class medicine of beta-blockerWith, digoxin is as the medicine of the 4th class coupling, further to improve symptom, to control heart rate etc. Aldosterone receptor antagonistBe applied to Serious heart Failure patient. But the taking of such medicine can cause the bad reactions such as headache, eye be dry, dizzy, therefore opensSend out a kind of and can effectively treat the pharmaceutical preparation that can reduce again side effect in heart failure, can greatly improve patient's compliance.The traditional Chinese medical science belongs to the categories such as " palpitation with fear ", " palpitation ", " dyspnea ", " phlegm and retained fluid ", " oedema ". Tcm diagnosis and treatment heart failureExhaust and accumulated abundant clinical experience, therapy and formula also has much characteristic, is relatively recognized that at present simulataneous insufficiency and excessive, asthenia in origin and asthenia in superficiality,This void is mainly gas sun virtual loss, also relates to cloudy wound, and internal organs are taking the heart as main, also relevant to kidney, spleen, lung; Mark is real is mainly bloodStasis of blood phlegm and retained fluid and water wet as suffering from. Guo Weiqin thinks that qi deficiency to blood stasis, edema due to yang insufficiency are the topmost interpretation of the cause, onset and process of an illness of heart failure, the heart qi deficiency, heart-yangVoid is its pathologic basis, and the blood vessels stasis of blood is stagnant is its key link. Under the guidance of theory of traditional Chinese medical science, also there are clinically some curativesThing, but these medicines exist uncertain therapeutic efficacy to cut more, the defect that result for the treatment of varies with each individual. Aim to provide one based on this present inventionKind of determined curative effect, treatment of congestive heart failure pharmaceutical composition that toxicity is low and preparation method thereof.
Summary of the invention
For lacking effective chemotherapeutics in existing treatment of congestive heart failure, the defect that toxic and side is large,For one congestion DHF medicine is safely and effectively provided, the clinical application that increases patients with congestive heart failure is selected,First object of the present invention is to provide a kind of Chinese medicine composition for the treatment of congestive heart failure, and this Chinese medicine composition is being controlledTreat congestive heart failure aspect and there is good result for the treatment of. Chinese medicine composition of the present invention, mainly by following weightThe raw material of part makes: 15 parts, Poria cocos, 8 parts, lotus leaf, 11 parts of sandburs, 12 parts of the Radixs Astragali, 9 parts of the roots of kudzu vine, 20 parts of the reds sage root,15 parts, the dried rhizome of rehmannia, 13 parts of peppermints, 5 parts of great burdock achenes, 5 parts of ginkgo leaves, 10 parts of the root of straight ladybell, 12 parts, date, 8 parts of pinellias,9 parts of reticulate millettias, 5 parts of Radix Angelicae Sinensis, 4 parts of pseudo-ginseng, 10 parts, Radix Glycyrrhizae.
Traditional Chinese medicinal components in Chinese medicine composition of the present invention is all got its conventional medicinal part and is used as medicine, and wherein the present composition has aobviousThe dispersing swelling and dissipating binds of work, activate blood circulation and disperse blood clots, effect of dispelling phlegm and eliminating dampness. Preferably, described Chinese medicine composition is by following weight portionRaw material makes: Poria cocos 15g, lotus leaf 8g, sandbur 11g, Radix Astragali 12g, root of kudzu vine 9g, red sage root 20g, dried rhizome of rehmannia 15g, thinLotus 13g, great burdock achene 5g, ginkgo leaf 5g, the root of straight ladybell 10g, date 12g, pinellia 8g, reticulate millettia 9g, Radix Angelicae Sinensis 5g, threeSeven 4g, Radix Glycyrrhizae 10g.
The method of preparing Chinese medicine composition of the present invention is as follows: get each medicinal material of above-mentioned components by weight percent, add medicinal material gross weight5-15 water doubly, soaks 10-60 minute, decocts 1-4 time, and each 1-3 hour, filters, merging filtrate, and filtrate decompression is denseBe reduced to the medicinal extract of relative density 1.05-1.25, this relative density is the testing result under 60 degrees Celsius, adds ethanol to containing alcoholAmount is 60-90% (v/v), leaves standstill 24 hours, gets supernatant, reclaims ethanol to concentrated, to obtain final product. The above-mentioned Chinese medicine of the present inventionComposition can further be prepared into conventional clinically pharmaceutical preparation, is preferably mixture, tablet, capsule.
The present invention also discloses a kind of purposes of above-mentioned Chinese medicine composition, and above-mentioned Chinese medicine composition is at the congested heart failure of preparation treatmentExhaust the purposes in medicine. Chinese medicine composition of the present invention has the result for the treatment of for the treatment of both principal and secondary aspect of disease for congestive heart failure. The present inventionEmbodiment 4 does the treatment of p-isopropyl adrenaline congestive heart failure rats model by investigating Chinese medicine composition of the present inventionWith confirming that each medication treatment group is compared with heart failure control group, heart rate (HR) all rises to some extent, left ventricular pressure rise/fall speedRate (± dp/dtmax) declines to some extent, embodies certain therapeutic action. Each composition treatment group compared with Carvedilol group, heart rateAscensional range, left ventricular pressure rise/fall speed are improved degree, left ventricular pressure peak value and left ventricular end diastolic pressure and are all depositedAt significantly (P < 0.05) or extremely significantly (P < 0.05) difference, show Chinese medicine composition of the present invention at heart failure therapy particularlyCongestive heart failure aspect has good result for the treatment of, and its result for the treatment of is better than conventional medicine Carvedilol.
In a word, the present invention compared with prior art, has the activity of fine treatment congestive heart failure, and the present invention isPure Chinese medicinal preparation, to human body particularly to liver nontoxicity. The present invention is during as treatment of congestive heart failure drug use,Drug effect is comprehensive, and sb.'s illness took a favorable turn can to make rapidly patients with congestive heart failure; And Chinese medicine composition preparation letter of the present inventionSingle, substantially nontoxic, raw material is easy to get, and is suitable for popular use, has good potential applicability in clinical practice.
Detailed description of the invention
Further describe the present invention by detailed description of the invention below, but the present invention is not limited only to following examples. At thisIn bright scope or not departing from content of the present invention, spirit and scope, Chinese medicine composition of the present invention is carried outSuitably improve, replace the identical component of effect, will become apparent to those skilled in the art that they are all regarded asComprise within the scope of the present invention.
Part I, the preparation of Chinese medicine composition of the present invention
Embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: Poria cocos 15g, lotus leaf 8g, sandbur 11g, Radix Astragali 12g, root of kudzu vine 9g, red sage root 20g, dried rhizome of rehmannia 15g, thinLotus 13g, great burdock achene 5g, ginkgo leaf 5g, the root of straight ladybell 10g, date 12g, pinellia 8g, reticulate millettia 9g, Radix Angelicae Sinensis 5g, threeSeven 4g, Radix Glycyrrhizae 10g.
Preparation method: get each medicinal material of above-mentioned components by weight percent, add the water of 5 times of medicinal material gross weight, soak 30 minutes, decoctBoil 2 times, each 2 hours, filter, merging filtrate, filtrate decompression is concentrated into the medicinal extract of relative density 1.1, this relative densityBe the testing result under 60 degrees Celsius, add ethanol to being 75% (v/v) containing alcohol amount, leave standstill 24 hours, get supernatant,Recovery ethanol is concentrated, adds water to 1000ml, stir evenly, and packing, flowing steam sterilization 35min, obtains mixture.
Embodiment 2 Chinese medicine composition tablet of the present invention
Prescription: Poria cocos 150g, lotus leaf 80g, sandbur 110g, Radix Astragali 120g, root of kudzu vine 90g, red sage root 200g, dried rhizome of rehmannia 150g,Peppermint 130g, great burdock achene 50g, ginkgo leaf 50g, the root of straight ladybell 100g, date 120g, pinellia 80g, reticulate millettia 90g, whenReturn 50g, pseudo-ginseng 40g, Radix Glycyrrhizae 100g.
Preparation method: get each medicinal material of above-mentioned components by weight percent, add the water of 10 times of medicinal material gross weight, soak 60 minutes, decoctBoil 1 time, each 1 hour, filter, merging filtrate, filtrate decompression is concentrated into the medicinal extract of relative density 1.25, and this is relatively closeDegree is the testing result under 60 degrees Celsius, adds ethanol to being 80% (v/v) containing alcohol amount, leaves standstill 24 hours, gets supernatant,Reclaim ethanol to concentrated, vacuum drying, granulation, compressing tablet and get final product.
Embodiment 3 Chinese medicinal composition capsules of the present invention
Prescription: Poria cocos 1500g, lotus leaf 800g, sandbur 1100g, Radix Astragali 1200g, root of kudzu vine 900g, red sage root 2000g,Dried rhizome of rehmannia 1500g, peppermint 1300g, great burdock achene 500g, ginkgo leaf 500g, the root of straight ladybell 1000g, date 1200g, pinellia 800g,Reticulate millettia 900g, Radix Angelicae Sinensis 500g, pseudo-ginseng 400g, Radix Glycyrrhizae 1000g.
Preparation method: get each medicinal material of above-mentioned components by weight percent, add the water of 8 times of medicinal material gross weight, soak 45 minutes, decoctBoil 4 times, each 1.5 hours, filter, merging filtrate, filtrate decompression is concentrated into the medicinal extract of relative density 1.2, and this is relatively closeDegree is the testing result under 60 degrees Celsius, adds ethanol to being 90% (v/v) containing alcohol amount, leaves standstill 24 hours, gets supernatant,Reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
Part II, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
The therapeutic action of embodiment 4 Chinese medicine composition p-isopropyl of the present invention adrenaline congestive heart failure rats model
1. modeling and grouping: clean 100 of level male SD rats 9 week age. Rat is divided into 2 groups at random: 90 of model group, subcutaneousInjection isoproterenol (ISO, 170mg/kg divide interval 24h 2 times), 10 of blank groups, hypodermic injection physiological saline(NS) 0.25ml. After modeling 6 weeks, application colorful ultrasonic monitor (model: HPSONOS5500, frequency probe 7.5MHz)Be positioned at mitral level with two-dimensional imaging pattern at left chamber minor axis tangent plane and measure index of correlation, measured value is to be measured 5 cardiac cycleAverage. Left Ventricular Ejection Fraction (LVEF)≤45% is modeling success. 85 of modeling success rats, modeling success rate is94.5％。
2. model grouping and administration: choose 60 of modeling success rats, adaptability was raised after a week, was divided at random 6 groups, every group 10Only. Gavage gives following medicine:
Model group (heart failure control group): gavage gives same volume physiological saline;
Carvedilol group: gavage gives 5.6mg/kg Carvedilol;
Low group of composition: gavage gives 0.5g/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition is by crude drug amount;
Group in composition: gavage gives 2g/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition is by crude drug amount;
Combination object height group: gavage gives 5g/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition is by crude drug amount;
The appropriate physiological saline solution of each group medicine, the equal gastric infusion of each treatment group, once a day, this experiment simultaneously all greatlyThe each treatment group rat of mouse is raised 18 weeks with chamber is conventional, feeding environment (22 ± 2) DEG C, and conventional feed is fed, and freely drinks water. TestedCheng Zhong, observes animal diet followed, survival condition and behavioral activity every day, measures weekly body weight (BW), adjusts medicine use according to body weightAmount.
3. index detects
Haemodynamics detects: l8 week experiment finishes, by rat with yellow Jackets 30mg/kg intraperitoneal injection of anesthesia after, shouldInsert left ventricle with left cardic catheter, by the defeated people BL-410 of pressure transducer biological function experimental system (the limited public affairs of Chengdu Tai Meng science and technologyDepartment), process and obtain left ventricular end diastolic pressure (LVEDP), left ventricular pressure peak value (LVSP), left ventricle by experimental system softwarePressure rise/decline maximum rate (± dp/dtmax), heart rate (HR).
The therapeutic action of table 1 compound p-isopropyl adrenaline congestive heart failure rats model
With model group comparison●P＜0.05，●●P < 0.01; Compared with Carvedilol group*P＜0.05，**P＜0.01；
As can be seen from Table 1, each medication treatment group is compared with heart failure control group, and heart rate (HR) all rises to some extent, left ventriclePressure rise/fall off rate (± dp/dtmax) declines to some extent, embodies certain therapeutic action. Each composition treatment group and card dimensionLip river, ground group is compared, and heart rate ascensional range, left ventricular pressure rise/fall speed are improved degree, left ventricular pressure peak value and the left heartAll there is significantly (P < 0.05) or extremely significantly (P < 0.05) difference in chamber end-diastolic pressure, shows that Chinese medicine composition of the present invention is at the heartForce failure is treated particularly congestive heart failure aspect and is had good result for the treatment of, and its result for the treatment of is better than conventional medicineCarvedilol.
Claims (5)
1. treat a Chinese medicine composition for congestive heart failure, it is characterized in that it is made by the bulk drug of following weight portion: Fu15 parts of Siberian cockleburs, 8 parts, lotus leaf, 11 parts of sandburs, 12 parts of the Radixs Astragali, 9 parts of the roots of kudzu vine, 20 parts of the reds sage root, 15 parts, the dried rhizome of rehmannia, peppermint13 parts, 5 parts of great burdock achenes, 5 parts of ginkgo leaves, 10 parts of the root of straight ladybell, 12 parts, date, 8 parts of pinellias, 9 parts of reticulate millettias, whenReturn 5 parts, 4 parts of pseudo-ginseng, 10 parts, Radix Glycyrrhizae.
2. Chinese medicine composition as claimed in claim 1, is characterized in that, it is made by the bulk drug of following weight portion: Poria cocos 15g,Lotus leaf 8g, sandbur 11g, Radix Astragali 12g, root of kudzu vine 9g, red sage root 20g, dried rhizome of rehmannia 15g, peppermint 13g, great burdock achene 5g, silverApricot leaf 5g, the root of straight ladybell 10g, date 12g, pinellia 8g, reticulate millettia 9g, Radix Angelicae Sinensis 5g, pseudo-ginseng 4g, Radix Glycyrrhizae 10g.
3. Chinese medicine composition as claimed in claim 1, is characterized in that described Chinese medicine composition is mixture, tablet or capsule.
4. prepare a method for Chinese medicine composition as claimed in claim 1 or 2, it is characterized in that it comprises the following steps: getEach medicinal material, the 5-15 that adds medicinal material gross weight water doubly, soaks 10-60 minute, decocts 1-4 time, and 1-3 hour at every turn, filtersCross, merging filtrate, filtrate decompression is concentrated into the medicinal extract of relative density 1.05-1.25, and this relative density is under 60 degrees CelsiusTesting result, adds ethanol to being 60-90% containing alcohol amount volume ratio, leaves standstill 24 hours, gets supernatant, reclaims ethanol to denseContracting, to obtain final product.
5. the purposes of the Chinese medicine composition described in claim 1 or 2 in preparation treatment congestive heart failure medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510149372.5A CN104688978B (en) | 2015-04-01 | 2015-04-01 | A kind of Chinese medicine composition for the treatment of congestive heart failure and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510149372.5A CN104688978B (en) | 2015-04-01 | 2015-04-01 | A kind of Chinese medicine composition for the treatment of congestive heart failure and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104688978A CN104688978A (en) | 2015-06-10 |
| CN104688978B true CN104688978B (en) | 2016-05-04 |
Family
ID=53336802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510149372.5A Active CN104688978B (en) | 2015-04-01 | 2015-04-01 | A kind of Chinese medicine composition for the treatment of congestive heart failure and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104688978B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101524469A (en) * | 2009-04-17 | 2009-09-09 | 山东大学齐鲁医院 | Chinese herbal medicine compound preparation for treating congestive heart failure and preparation method thereof |
-
2015
- 2015-04-01 CN CN201510149372.5A patent/CN104688978B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101524469A (en) * | 2009-04-17 | 2009-09-09 | 山东大学齐鲁医院 | Chinese herbal medicine compound preparation for treating congestive heart failure and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 严世芸教授辨治慢性充血性心力衰竭临证经验;郭美珠等;《辽宁中医药大学学报》;20120229;第82-85页 * |
| 中医对慢性充血性心力衰竭的认识及治疗进展;王利霞;《中西医结合心脑血管病杂志》;20090710(第07期);第814-816页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104688978A (en) | 2015-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103816280B (en) | Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition | |
| CN102048821B (en) | Method for preparing perhexiline pharmaceutical preparation | |
| CN108619355A (en) | A kind of antitumor Chinese and preparation method thereof | |
| CN103721075B (en) | A kind of Chinese medicine for post gynecologic operation and preparation method thereof | |
| CN108403882A (en) | A kind of red sage root composition and preparation method thereof for treating coronary heart disease | |
| CN105287812A (en) | Medicine composition for treating irritable bowel syndromes and application of medicine composition | |
| CN101584810A (en) | Medicine composition for treating gastritis and peptic ulcer and preparation method thereof | |
| CN102579610A (en) | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof | |
| CN104688978B (en) | A kind of Chinese medicine composition for the treatment of congestive heart failure and preparation method thereof | |
| CN104922528B (en) | A kind of pharmaceutical composition and its preparation method and application for treating malignant pleural effusion | |
| CN107998315A (en) | A kind of compound Chinese medicinal preparation for treating hyperuricemia | |
| CN102861232A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hypertension | |
| CN101632783B (en) | Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN104524359B (en) | A kind of Chinese medicine composition, its preparation method and application | |
| CN104189314B (en) | It is a kind of to treat the turbid pharmaceutical composition for checking card high fat of blood of phlegm | |
| CN103655969A (en) | Traditional Chinese medicine composition with functions of regulating blood pressure and blood glucose and preparation method thereof | |
| CN102526628B (en) | Medicinal composition for treating myocardial infarction | |
| CN102895514B (en) | Application of Chinese medicine composition in preparing medicines for treating pulmonary heart disease | |
| CN109568481A (en) | A kind of Chinese prescription preparation for treating coronary heart disease | |
| CN106581468A (en) | Preparation method of traditional Chinese medicine capable of treating gastric ulcer | |
| CN101152247A (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN106620439B (en) | For the pharmaceutical composition of Postoperative analgesia, preparation and its application | |
| CN104587278A (en) | Traditional Chinese medicinal composition for treating pleural effusion and preparation method | |
| CN104940554A (en) | Chinese herbal composition for treating heart diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Pingzheng Inventor after: Yang Fang Inventor before: The inventor has waived the right to be mentioned |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160317 Address after: 266300 Department of Cardiology, Jiaozhou Central Hospital, 29 Xuzhou Road, Jiaozhou District, Shandong, Qingdao, Qingdao Applicant after: Wang Pingzheng Address before: 266109 Shandong, Qingdao, Chengyang District, No. 825 Zhengyang Road, building, room 1, office, room 205 Applicant before: The skies, Qingdao Bioisystech Co., Ltd |
|
| CB02 | Change of applicant information |
Address after: 266300 Department of Cardiology, Jiaozhou Central Hospital, Xuzhou Road, 29 Jiaozhou Road, Qingdao, Shandong, Qingdao Applicant after: Wang Pingzheng Address before: 266300 Department of Cardiology, Jiaozhou Central Hospital, 29 Xuzhou Road, Jiaozhou District, Shandong, Qingdao, Qingdao Applicant before: Wang Pingzheng |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190529 Address after: 311200 Zidong Village, Heshang Town, Xiaoshan District, Hangzhou City, Zhejiang Province Patentee after: Hangzhou Sangjiefei Technology Co., Ltd. Address before: 266300 Department of Cardiology, Qingdao Jiaozhou Central Hospital, 29 Xuzhou Road, Qingdao City, Shandong Province Patentee before: Wang Pingzheng |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20200628 Address after: 314100 C7 building 201, Chuang Road, Dayun Town, Jiashan, Jiaxing, Zhejiang, 201 Patentee after: JIAXING LAIPUSHENG MEDICAL TECHNOLOGY Co.,Ltd. Address before: 311200 Zidong Village, Heshang Town, Xiaoshan District, Hangzhou City, Zhejiang Province Patentee before: Hangzhou Sangjiefei Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |